News

VP025 is being developed to target the chronic inflammation within the central nervous system that is associated with a number of neurological diseases, including Alzheimer’s disease, Parkinson’s disease,

The results showed that Procyon’s PL-100 and its back-up analogue PL-337 had the most favorable cross-resistance profile of all the protease inhibitors (PIs) studied, as measured by the

ViroLogic’s novel HIV resistance testing technology will be used across GSK’s virology portfolio, including its entry inhibitor program, where a ViroLogic assay will be used to identify patients

Antisoma is evaluating options for the further development of Aptamera’s lead product, AGRO100, which is now redesignated AS1411. The next step will be either a phase II study

Intendis management introduced the new company and its growth prospects at a press conference in Berlin, Germany. The company plans to invest in the marketing of the group’s

These compounds are the first to be invented by Speedel Experimenta, the company’s late-stage research unit, which was established in 2002. SPP630 and SPP635 have now been successfully

Ceftobiprole has activity against methicillin-resistant Staphylococcus aureus (MRSA) and is in phase III clinical trials in complicated skin and skin structure infections, with hospital-acquired pneumonia trials also in

Bexxar, a new form of treatment for lymphoma that takes a fraction of the time of traditional chemotherapy and with fewer side effects, was evaluated in patients with

Carpal tunnel syndrome (CTS) is marked by numbness, weakness, and pain in the wrist, hand and arm, and occurs when the median nerve, which runs from the forearm